Una nueva combinación de fármacos orales es eficaz contra la hepatitis C
Agencia SINC,
Un estudio demuestra que, con la administración de dos antivirales, entre el 87 y el 98% de las personas con el virus de la…
Articles Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir MK5172 and elbasvir MK8742 with or without ribavirin in patients with hepatitis C virus genotype 1 monoinfection and HIVhepatitis C virus coinfection CWORTH
Bioportfolio,
Oncedaily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCVmonoinfected and…
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment GrazoprevirElbasvir in Genotype 1 Infected TreatmentNave and DifficulttoCure Patients
Bioportfolio,
Final Results from the CWORTHy Study Parts A and B Presented at The Liver Meeting and Published in The Lancet First Wave of…